Market Access News | pharmaphorum

News

Fabhalta is first FDA-approved therapy for rare disease C3G

Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.

News

J&J adds to IL-23 options in Crohn's after FDA approval

J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.

News

Alnylam joins three-way contest in ATTR cardiomyopathy

Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.

News

UK is becoming an 'outlier' for pharma, hitting investment

UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.

News

J&J's nipocalimab fast-tracked for Sjogren's disease

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.

News

FDA chooses flu vaccine strains despite cancelled meeting

The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season – without the input of its external advisors.

Fabhalta is first FDA-approved therapy for rare disease C3G

J&J adds to IL-23 options in Crohn's after FDA approval

Alnylam joins three-way contest in ATTR cardiomyopathy

UK is becoming an 'outlier' for pharma, hitting investment

J&J's nipocalimab fast-tracked for Sjogren's disease

FDA chooses flu vaccine strains despite cancelled meeting

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks